يعرض 1 - 10 نتائج من 12 نتيجة بحث عن '"Yolla El-Dakdouki"', وقت الاستعلام: 1.03s تنقيح النتائج
  1. 1
    Sequence analyses of relapsed or refractory diffuse large B‐cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH‐EP1 study

    المؤلفون: Jean‐Marie Michot, Cyril Quivoron, Clémentine Sarkozy, Alina Danu, Julien Lazarovici, Khalil Saleh, Yolla El‐Dakdouki, Vincent Goldschmidt, Camille Bigenwald, Matteo Dragani, Rastislav Bahleda, Capucine Baldini, Julia Arfi‐Rouche, Patricia Martin‐Romano, Lambros Tselikas, Anas Gazzah, Antoine Hollebecque, Ludovic Lacroix, David Ghez, Veronique Vergé, Christophe Marzac, Sophie Cotteret, Wassila Rahali, Jean‐Charles Soria, Christophe Massard, Olivier A. Bernard, Peggy Dartigues, Valérie Camara‐Clayette, Vincent Ribrag

    المصدر: American Journal of Hematology. 98:645-657

    مصطلحات موضوعية: Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::83c09f85453cac881c334c43ddbe2644
    https://doi.org/10.1002/ajh.26835

    View record at Wiley
    أضف إلى المفضلة
  2. 2
    Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study

    المؤلفون: Jean-Marie, Michot, Cyril, Quivoron, Clémentine, Sarkozy, Alina, Danu, Julien, Lazarovici, Khalil, Saleh, Yolla, El-Dakdouki, Vincent, Goldschmidt, Camille, Bigenwald, Matteo, Dragani, Rastislav, Bahleda, Capucine, Baldini, Julia, Arfi-Rouche, Patricia, Martin-Romano, Lambros, Tselikas, Anas, Gazzah, Antoine, Hollebecque, Ludovic, Lacroix, David, Ghez, Veronique, Vergé, Christophe, Marzac, Sophie, Cotteret, Wassila, Rahali, Jean-Charles, Soria, Christophe, Massard, Olivier A, Bernard, Peggy, Dartigues, Valérie, Camara-Clayette, Vincent, Ribrag

    المصدر: American journal of hematology.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=pmid________::aa1f2f1bd60bfe09f1265db9440e311b
    https://pubmed.ncbi.nlm.nih.gov/36606708

    View record at Wiley
    أضف إلى المفضلة
  3. 3
    Attenuated cytarabine, etoposide, dexamethasone plus rituximab (R‐Mini‐CYVE) regimen for patients with relapsed or refractory B‐cell non–Hodgkin’s lymphoma not eligible for intensive chemotherapy

    المؤلفون: Christophe Willekens, Romain Desmaris, Peggy Dartigues, Alina Danu, Julien Lazarovici, Christophe Fermé, David Ghez, Nathalie Ibrahim, Yolla El Dakdouki, Julien Rossignol, Pamela Abdayem, Jean M. Michot, Julia Arfi Rouche, Vincent Ribrag

    المصدر: European Journal of Haematology. 106:574-583

    مصطلحات موضوعية: Adult, Male, medicine.medical_specialty, Lymphoma, B-Cell, Cytarabine/Etoposide, Comorbidity, Gastroenterology, Dexamethasone, 03 medical and health sciences, 0302 clinical medicine, hemic and lymphatic diseases, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Etoposide, Aged, Aged, 80 and over, Performance status, business.industry, Lymphoma, Non-Hodgkin, Cytarabine, Hematology, General Medicine, Middle Aged, Prognosis, medicine.disease, Regimen, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Female, Rituximab, business, Diffuse large B-cell lymphoma, 030215 immunology, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d48ef07cf1dede0215af385c259cc141
    https://doi.org/10.1111/ejh.13589

    View record at Wiley
    أضف إلى المفضلة
  4. 4
    Sequence Analyses of Relapsed or Refractory Diffuse Large B-Cell Lymphomas Unravels Three Genetic Subgroups of Patients and GNA3 Mutant as Poor Prognosis Biomarker, Results of LNH-EP1 Study

    المؤلفون: Jean-Marie Michot, Cyril Quivoron, Clémentine Sarkozy, Alina Danu, Julien Lazarovici, Khalil Saleh, Yolla El-Dakdouki, Vincent Goldschmidt, Camille Bigenwald, Matteo Dragani, Rastislav Bahleda, Capucine Baldini, Julia Arfi-Rouche, Patricia Martin-Romano, Lambros Tselikas, Anas Gazzah, Antoine Hollebecque, Ludovic Lacroix, David Ghez, Veronique Vergé, Christophe Marzac, Sophie Cotteret, Wassila Rahali, Jean-Charles Soria, Christophe Massard, Olivier A. Bernard, Peggy Dartigues, Valérie Camara-Clayette, Vincent Ribrag

    المصدر: SSRN Electronic Journal.

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::71c291d749d32fce7c73d8413df39b78
    https://doi.org/10.2139/ssrn.4057122

    أضف إلى المفضلة
  5. 5
    Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1

    المؤلفون: Mathilde Fusellier, Stéphane Champiat, Anne-Laure Voisin, Capucine Baldini, François-Xavier Danlos, Maxime Annereau, Olivier Lambotte, Christine Mateus, Caroline Robert, Aurélien Marabelle, C. Velter, Jean-Marie Michot, Khadija Cherif, Xavier Mariette, Yolla El Dakdouki

    المصدر: Annals of the rheumatic diseases. 78(7)

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, medicine.medical_treatment, Immunology, medicine.disease_cause, General Biochemistry, Genetics and Molecular Biology, Autoimmunity, Immune tolerance, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Internal medicine, Neoplasms, Pharmacovigilance, Immunology and Allergy, Medicine, Humans, Immunologic Factors, Lupus Erythematosus, Systemic, Prospective Studies, Drug-induced lupus erythematosus, Adverse effect, 030203 arthritis & rheumatology, Lupus erythematosus, business.industry, Cancer, Immunotherapy, medicine.disease, 030104 developmental biology, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bb572d3ed9ab76bdfa73638088a6b8f8
    https://pubmed.ncbi.nlm.nih.gov/29934372

    Find this article in full text from ProQuest
    أضف إلى المفضلة
  6. 6
    Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

    المؤلفون: Anas Gazzah, Jean-Yves Scoazec, Sophie Postel-Vinay, Eric Deutsch, Antoine Hollebecque, Yolla El Dakdouki, Christophe Massard, Eric Solary, Ludovic Lacroix, Monica Arnedos, Etienne Rouleau, Jean-Pierre Armand, Loic Verlingue, Stefan Michiels, Fabrice Andre, Andrea Varga, Rastilav Balheda, Jean-Charles Soria, Capucine Baldini, Eric Angevin, Aurélien Marabelle, Thierry de Baere, Jean-Marie Michot, Olivier Mir

    المصدر: European journal of cancer (Oxford, England : 1990). 92

    مصطلحات موضوعية: 0301 basic medicine, Male, Cancer Research, Time Factors, Receptor, ErbB-3, Afatinib, medicine.medical_treatment, DNA Mutational Analysis, Tyrosine-kinase inhibitor, Targeted therapy, 0302 clinical medicine, Trastuzumab, Risk Factors, Neoplasms, Molecular Targeted Therapy, Precision Medicine, Comparative Genomic Hybridization, High-Throughput Nucleotide Sequencing, Middle Aged, Phenotype, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Female, Tyrosine kinase, medicine.drug, Signal Transduction, Adult, medicine.drug_class, Antineoplastic Agents, Lapatinib, Disease-Free Survival, 03 medical and health sciences, Germline mutation, Predictive Value of Tests, Exome Sequencing, medicine, Biomarkers, Tumor, Humans, Genetic Predisposition to Disease, Protein Kinase Inhibitors, Aged, Proportional Hazards Models, Retrospective Studies, business.industry, Cancer, medicine.disease, 030104 developmental biology, Mutation, Cancer research, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcffd5c03c7c6b4e2c0185bcbf8bb5b
    https://pubmed.ncbi.nlm.nih.gov/29413684

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  7. 7
    Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations

    المؤلفون: Yolla El Dakdouki, Julia Salleron, Yoan Ditchi, Pernelle Lavaud, Marie-Christine Mathieu, Chloé Broudin, Patrick R. Benusiglio, Donia Lejri, Caroline Baynes, Marie Muller, Olivier Caron

    المساهمون: Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Université Paris-Saclay, Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER, University of Cambridge [UK] (CAM), Département de biologie et pathologie médicales [Gustave Roussy], Unité fonctionnelle d'Oncogénétique et Angiogénétique Moléculaire [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

    المصدر: The Breast Journal
    The Breast Journal, 2019, 25 (1), pp.16-19. ⟨10.1111/tbj.13154⟩

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Heterozygote, endocrine system diseases, [SDV]Life Sciences [q-bio], Genetic counseling, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Breast Neoplasms, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, Internal medicine, Internal Medicine, medicine, Genetic predisposition, Humans, Genetic Predisposition to Disease, Li-Fraumeni syndrome, TP53, skin and connective tissue diseases, education, Germ-Line Mutation, BRCA2 Protein, education.field_of_study, business.industry, BRCA1 Protein, Cancer, BRCA1, medicine.disease, BRCA2, 3. Good health, genetic susceptibility to disease, body regions, Carcinoma, Lobular, Carcinoma, Intraductal, Noninfiltrating, Li–Fraumeni syndrome, 030220 oncology & carcinogenesis, Invasive lobular carcinoma, invasive lobular carcinoma of the breast, Surgery, Female, Tumor Suppressor Protein p53, Ovarian cancer, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7bf79589336c685e0f3f02dd2c2bbd89
    https://pubmed.ncbi.nlm.nih.gov/30414230

    أضف إلى المفضلة
  8. 8
    Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine

    المؤلفون: Patricia Kannouche, Nathalie Chaput, Said Aoufouchi, Laetitia Nebot-Bral, Stéphane Champiat, David Brandao, David Malka, Emmanuelle Despras, Olivier Caron, Aurélien Marabelle, Loic Verlingue, Alexandra Leary, Yolla El-Dakdouki, Etienne Rouleau

    المصدر: European journal of cancer (Oxford, England : 1990). 84

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_treatment, DNA Mutational Analysis, Pembrolizumab, Biology, DNA Mismatch Repair, 03 medical and health sciences, 0302 clinical medicine, Immune system, Antigens, Neoplasm, Predictive Value of Tests, Neoplasms, medicine, Biomarkers, Tumor, Tumor Microenvironment, Humans, Genetic Predisposition to Disease, Molecular Targeted Therapy, Precision Medicine, Poly-ADP-Ribose Binding Proteins, DNA Polymerase III, Tumor microenvironment, Microsatellite instability, Immunotherapy, DNA Polymerase II, Precision medicine, medicine.disease, 030104 developmental biology, Phenotype, Oncology, Tumor Escape, 030220 oncology & carcinogenesis, Immunology, Mutation, Cancer research, DNA mismatch repair, Microsatellite Instability

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f69dfc275cd33e1e5773525884cb272
    https://pubmed.ncbi.nlm.nih.gov/28846956

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  9. 9
    Abstract 2953: Overall survival results of the single-institution molecular screening MOSCATO trial in hard-to-treat advanced cancers

    المؤلفون: Adrien Allorant, Lambros Tselikas, Loic Verlingue, Yolla El Dakdouki, Christophe Massard, Cécile Jovelet, Stefan Michiels, Thierry Debaere, Fabrice Andre, Jean-Charles Soria, A. Hollebecque, Ludovic Lacroix, Gilles Vassal, Etienne Rouleau, Nathalie Auger

    المصدر: Cancer Research. 78:2953-2953

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Molecular screening, business.industry, Internal medicine, Overall survival, Medicine, Single institution, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5385290cd3697466428ce9d8ce0d1f70
    https://doi.org/10.1158/1538-7445.am2018-2953

    أضف إلى المفضلة
  10. 10
    Abstract CT141: Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial)

    المؤلفون: Andreea Varga, Jessica Menis, Jean-Marie Michot, Aurélien Marabelle, Yolla El-Dakdouki, Xavier Paoletti, Christophe Massard, Anas Gazzah, David Planchard, Saloomeh Rafie, Patricia Martin-Romano, Benjamin Besse, Vincent Ribrag, Capucine Baldini, Antoine Hollebecque, Rastislav Bahleda, Stéphane Champiat, Jean-Charles Soria

    المصدر: Cancer Research. 78:CT141-CT141

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, business.industry, Pembrolizumab, chemistry.chemical_compound, chemistry, Internal medicine, medicine, Dose escalation, Nintedanib, In patient, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::310285bcae7d61e8839afc0efd4e5e28
    https://doi.org/10.1158/1538-7445.am2018-ct141

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء